Diagnosis and Management of Advanced Gallbladder Carcinoma

Imaging and Staging

The American College of Radiology recommends the use of PET-CT for complete staging of gallbladder cancer, as it changes management in 23.4% of patients with apparently resectable disease on CECT alone 1, 2
MRI abdomen with MRCP is valuable for assessing biliary anatomy and vascular involvement, and provides better definition of tumor extent and liver metastases than CT 2, 3
The presence of multiple peripherally enhancing hypodense liver lesions (up to 17mm) represents likely intrahepatic metastases, and enlarged necrotic periportal and mesenteric lymph nodes (12mm) suggest N1 disease 3, 4

The American Gastroenterological Association suggests that biopsy risks tumor spillage and has high false-negative rates (30-60%), and definitive pathology will be obtained at surgery 3, 6
ERCP with brush cytology may be considered if biliary decompression is needed for cholangitis or if staging reveals unresectable disease requiring palliative stenting, with a combined yield of 40-70% sensitivity 3, 6

The Society of Surgical Oncology recommends en-bloc resection of involved duodenum and hepatic flexure, regional lymphadenectomy, and reconstruction with hepaticojejunostomy and bowel anastomoses for resectable disease 4

The National Comprehensive Cancer Network recommends initiating palliative chemotherapy with gemcitabine-based regimens for advanced gallbladder cancer, and ERCP with biliary stenting for symptomatic obstruction 6

The Infectious Diseases Society of America recommends starting broad-spectrum antibiotics immediately given the cholecystoenteric fistulas and pneumobilia, with piperacillin/tazobactam 4g/0.5g IV every 6 hours covering enteric organisms from fistulas 7

The American Society of Clinical Oncology suggests that CA 19-9 monitoring can detect recurrence, though its role in surveillance is not well-established, and surveillance imaging every 3-4 months for 2 years then every 6 months is recommended 3, 5, 6